SUPN — SUPERNUS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356576 ·
Last close
$42.14
Market Cap
$2.45B
52W High
$59.68
52W Low
$40.51
ADV30
642,475
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 219,058,000 | 185,389,000 | -3,044,000 | -58,371,000 | 1,428,109,000 | 179,953,000 | 396,883,000 |
| Mar 2026 | 207,705,000 | 184,314,000 | -5,941,000 | -2,293,000 | 1,500,725,000 | 184,869,000 | 423,920,000 |
| Dec 2025 | 211,572,000 | 188,565,000 | 13,822,000 | -4,105,000 | 1,452,648,000 | 128,448,000 | 390,934,000 |
| Sep 2025 | 192,103,000 | 173,138,000 | -60,231,000 | -45,117,000 | 1,419,754,000 | 151,371,000 | 370,087,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,911,000
Investing CF
$-14,728,000
Financing CF
$31,509,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$457,212,000
Inventory
$83,924,000
Receivables
$211,656,000
ST Investments
$192,114,000
EBIT TTM
$-119,849,000
Pretax Income TTM
$-123,466,000
Interest Exp TTM
$2,315,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$830,438,016
EBITDA
$110,432,000
Free Cash Flow
$84,611,000
Enterprise Value
$2,088,511,872
Total Cash
$372,067,008
Total Debt
$40,170,000
Shares Out
58,127,013
Trailing EPS
$-1.92
Book Value
$17.73
ROE
-10.5%
ROA
0.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 718,952,000 | -36,864,000 | -38,550,000 | 1,452,648,000 | 390,934,000 | 1,061,714,000 | 47,331,000 |
| Dec 2024 | 661,817,000 | 75,556,000 | 73,865,000 | 1,368,073,000 | 332,340,000 | 1,035,733,000 | 171,951,000 |
| Dec 2023 | 607,521,000 | 13,403,000 | 1,316,000 | 1,277,673,000 | 356,157,000 | 921,516,000 | 111,085,000 |
| Dec 2022 | 667,238,000 | 45,614,000 | 60,711,000 | 1,702,508,000 | 816,304,000 | 886,204,000 | 116,826,000 |
TTM Snapshot
Revenues TTM
$776,833,000
NetIncome TTM
$-29,016,000
OpCashFlow TTM
—
Assets (Latest)
$1,500,725,000
Forward EPS
$4.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | $2.49B | $21.26 | — |
| LQDA | Liquidia Corp | $2.51B | $28.02 | — |
| HCM | HUTCHMED (China) Ltd | $2.38B | $13.67 | — |
| MBX | MBX Biosciences, Inc. | $2.56B | $53.25 | — |
| IRON | Disc Medicine, Inc. | $2.33B | $60.77 | — |
News headlines (Yahoo Finance, 1h cache)
1 Healthcare Stock Worth Your Attention and 2 We Turn Down
2026-10-09 12:11 · Yahoo
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
2026-09-21 21:18 · Yahoo
Why Did Supernus Pharmaceuticals (SUPN) Move Today?
2026-09-19 00:19 · Yahoo
How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook
2026-09-18 19:12 · Yahoo
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
2026-09-18 14:48 · Yahoo
Supernus Pharmaceuticals to Participate in September Investor Conferences
2026-09-02 20:30 · Yahoo
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
2026-08-24 21:45 · Yahoo
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
2026-09-28 13:41 · Yahoo
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
2026-09-28 05:00 · Yahoo
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
2026-09-25 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.